ENCORE MEDICAL, INC.

Encore Medical, Inc. is a cardiovascular device company specializing in transcatheter closure devices for congenital heart defects. Founded in October 2020, the company builds on over 20 years of international transcatheter closure device experience, with more than 25,000 devices successfully implanted globally. Encore's primary product portfolio includes the Encore Patent Foramen Ovale (PFO) Closure Device and the Encore Atrial Septal Defect (ASD) Closure Device, both designed for percutaneous, catheter-based implantation to close abnormal communications between cardiac chambers. The Encore PFO device prevents embolic stroke by closing unwanted communications between right and left atria, offering features including full retrievability, minimal blood flow disturbance, and conformance to patient anatomy. The Encore ASD device provides similar closure capabilities for atrial septal defects in pediatric and adult patients across multiple sizing options. Both devices are supported by the proprietary Encore Delivery System, a catheter-based platform available in multiple French sizes (9–12 Fr) with self-sealing introducers and positive locking mechanisms for device release. The company is currently conducting the PerFOrm randomized controlled trial comparing the Encore PFO device to FDA-approved alternatives, intended to support US regulatory approval. Encore's devices are based on patented technology platforms with demonstrated clinical performance outside the United States. The company operates from Eagan, Minnesota, and focuses on interventional cardiology and structural heart disease markets.